Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS)

CAPS Rating: 2 out of 5

The Company is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other unmet medical needs.

Recs

0
Player Avatar theMANzalone (83.42) Submitted: 3/14/2012 4:05:12 PM : Outperform Start Price: $2.45 SNSS Score: +132.79

2013 will kick into gear

Featured Broker Partners


Advertisement